News

Filter

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Abbott/Eisai's Humira has emerged as leading psoriasis agent

07-08-2012

For the treatment of psoriasis, Abbott/Eisai's Humira (adalimumab) has displaced Amgen/Stiefel/Pfizer/Takeda's…

Abbott LaboratoriesAmgenAnti-Arthritics/RheumaticsBiotechnologyEisaiEnbrelGlobalHumiraImmunologicalsJanssenMarkets & MarketingPfizerPharmaceuticalStelara Injection

Psoriasis drug market expected to double to $6.8 Billion in 2019, driven by biologics penetration and Interleukin/TNF-alpha inhibitors

10-08-2010

The continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors, along with a twofold…

BiotechnologyDermatologicalsEnbrelHumiraMarkets & MarketingPharmaceuticalStelara Injection

Back to top